Form 4: Apellis Officer Sells Shares for Tax Withholding

Apellis Pharmaceuticals' VP/Chief Accounting Officer, James Chopas, sold 873 shares of common stock to cover tax obligations related to RSU vesting.

Summary

• James George Chopas, VP/Chief Accounting Officer of Apellis Pharmaceuticals, Inc., reported a sale of common stock.
• The transaction involved 873 shares of Apellis Pharmaceuticals common stock.
• The shares were sold at a price of $22.1872 per share.
• The sale was executed on January 13, 2026.
• The purpose of the sale was to cover tax withholding obligations on Restricted Stock Units (RSUs) that vested on January 12, 2026.
• Following this transaction, Mr. Chopas beneficially owns 52,595 shares of Apellis Pharmaceuticals common stock directly.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The transaction is a routine tax-related sale under a 10b5-1 plan, which is generally not a negative signal. The slight positive comes from the transparency and pre-planned nature.

Positives

• The transaction was pre-planned under a Rule 10b5-1(c) plan, indicating a structured approach to equity management rather than an opportunistic sale.
• The sale was for tax withholding purposes, which is a common and routine event for executives receiving equity compensation.

Negatives

• A reduction in direct beneficial ownership by an executive, although for tax purposes, still represents a decrease in their direct stake.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries for executives receiving equity compensation. It does not reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• The sale of shares to cover tax withholding on RSU vesting is a standard practice for executives across publicly traded companies, aligning with typical equity compensation management.
• Many companies, including peers in the biotechnology and pharmaceutical sectors like Biogen (BIIB) or Vertex Pharmaceuticals (VRTX), have executives who execute similar tax-related sales upon RSU vesting.
• The use of a Rule 10b5-1 plan for such transactions is also a common corporate governance practice to mitigate concerns about insider trading.

Corporate Governance

Stakeholder Impact

• Shareholders: Minimal direct impact. A small reduction in executive ownership, but for a routine tax purpose, unlikely to signal a lack of confidence. The 10b5-1 plan provides transparency.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned sale of shares by an executive to cover tax obligations related to RSU vesting. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or the executive's confidence. Therefore, it provides no new information that would warrant a change in investment recommendation; a "hold" stance is appropriate based solely on this filing.

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Executive Compensation, James Chopas, Rule 10b5-1